Kestra Medical Technologies Ltd

KMTS remains in a Stage 2 uptrend on the medium and long term, but recent short-term momentum has rolled over into a pullback toward the 50-day SMA with the 9- and 20-day EMAs flattening. RSI has cooled from overbought into neutral. Execution is deferred (Stalk) around the support zone near the 50-day SMA until a clear reversal emerges, such as a hold and bounce off that level or a reclaim of the 9-day EMA.

• ↑Q4 2026 revenue up 66% YoY to $28.6M driven by WCD adoption
• ↑Maintains $262M cash plus $200M non-dilutive debt facility for operations
• ↓Net loss of $0.67 per share missed estimates, highlighting profitability gap